Phase II study of S-1+CPT-11+Bevacizumab as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1+L-OHP+Bevacizumab
Ontology highlight
ABSTRACT: Interventions: Bevacizumab 7.5mg/kg/tri-week CPT-11 150mg/m2/tri-week S-1 40-60mg/twice/day(day1-15)/tri-week
Primary outcome(s): Progression-free survival
Study Design: Single arm Non-randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2630432 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA